Ihsan AYHAN, Sehmus ERTOP

The effects of mean platelet volume and red cell distribution width on prognosis in patients with myelodysplastic syndrome

Anahtar Kelimeler:

Myelodysplastic syndrome; Mean platelet volume; Red cell distribution width; Treatment response, Myelodysplastic syndrome, Mean platelet volume, Red cell distribution width, Treatment response

The effects of mean platelet volume and red cell distribution width on prognosis in patients with myelodysplastic syndrome

Objective: In this study, the relationship between changes in mean platelet volume (MPV) and erythrocyte distribution width (RDW) with hematological response and survival in patients with myelodysplastic syndrome was investigated. Patients and Methods: Between 1 January 2011 and 31 December 2018, patient characteristics and hemogram results were evaluated during the treatment process among 158 patients diagnosed with myelodysplastic syndrome. Results: The mean age of the patients who were included in the study was 71.53±12.6 years. The MPV percentage change in the 2-year follow-up of the patients with and without hematological response was significant, at 0.022±0.11 (2.2%) in those who responded and at 0.069±0.15 (6.9%) in those who did not (p=0.049). Throughout the same period, the degree of RDW changes in the patients who died was 13.23±22.97, the degree in those who survived was 2.86±21.42, and the difference between the two groups was statistically significant (p=0.006). Conclusion: In patients diagnosed with myelodysplastic syndrome, MPV and RDW values can be considered inexpensive and simple laboratory markers that can be used in follow-ups and promising tests to predict both treatment response and survival in the early period and change treatment modalities.

Keywords:

Myelodysplastic syndrome, Mean platelet volume, Red cell distribution width, Treatment response,

PDF

___

Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189- 99. doi.org/10.1111/j.1365-2141.1982.tb02771.x
Chu SG, Becker RC, Berger PB, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and metaanalysis. J Thromb Haemost 2010;8:148-56. doi.org/10.1111/ j.1538-7836.2009.03584.x
Fiore M, Pillois X, Lorrain S, et al. A diagnostic approach that may help to discriminate inherited thrombocytopenia from chronic immune thrombocytopenia in adult patients. Platelets 2016;27:555-62. doi.org/10.3109/09537.104.2016.1143920
Evans TC, Jehle D. The red blood cell distribution width. J Emerg Med 1991;9:71-4. doi.org/10.1016/0736- 4679(91)90592-4
Hsieh YP, Chang CC, Kor CT, Yang Y, Wen YK, Chiu PF. The predictive role of red cell distribution width in mortality among chronic kidney disease patients. PLoS One 2016;11: e0162025. doi.org/10.1371/journal.pone.0162025
Patel K V, Semba RD, Ferrucci L, Newman AB, Fried LP, Wallace RB, et al. Red cell distribution width and mortality in older adults: a meta-analysis. Journals Gerontol 2009;65:258- 65. doi.org/10.1093/gerona/glp163
Montagnana M, Cervellin G, Meschi T, Lippi G. The role of red blood cell distribution width in cardiovascular and thrombotic disorders. Clin Chem Lab Med 2012;50:635-41. doi.org/10.1515/cclm.2011.831
Masutani R, Ikemoto T, Maki A, et al. Mean platelet component and mean platelet volume as useful screening markers for myelodysplastic syndrome. Heal Sci Reports 2018;1:1-6. doi. org/10.1002/hsr2.50
Tekinalp A, Ceneli O, Demircioglu S, Celik AF. The effect of neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR) and mean platelet volume to thrombocyte ratio (MPV/PLT) on survival in myelodysplastyc syndrome. Ann Med Res 2022;29:434-8. doi.org/10.5455/ annalsmedres.2021.07.503
Baba Y, Saito B, Shimada S, et al. Association of red cell distribution width with clinical outcomes in myelodysplastic syndrome. Leuk Res 2018;67:56-9. doi.org/10.1016/j. leukres.2018.02.004
Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-65. doi.org/10.1182/ blood-2012-03-420489
Neukirchen J, Schoonen WM, Strupp C, et al. Incidence and prevalence of myelodysplastic syndromes: Data from the Düsseldorf MDS-registry. Leuk Res 2011;35:1591-6. doi. org/10.1016/j.leukres.2011.06.001
Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza- 2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000;18:956-62. doi.org/10.1200/jco.2000.18.5.956
Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88. doi.org/10.1182/blood.V89.6.2079
Turgutkaya A, Akın N, Sargın G, Bolaman Z, Yavaşoğlu İ. The relationship between red cell distribution width and prognostic scores in myelodysplastic syndrome. Hematol Transfus Cell Ther 2022;44:332-5. doi.org/10.1016/j. htct.2020.11.007